The benefit of adopting Microultrasound in the prostate cancer imaging pathway : A lesion-by-lesion analysis.

Details

Serval ID
serval:BIB_8CFD71B1DDEF
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The benefit of adopting Microultrasound in the prostate cancer imaging pathway : A lesion-by-lesion analysis.
Journal
Progres en urologie
Author(s)
Martel P., Rakauskas A., Dagher J., La Rosa S., Meuwly J.Y., Roth B., Valerio M.
ISSN
1166-7087 (Print)
ISSN-L
1166-7087
Publication state
Published
Issued date
12/03/2022
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
Microultrasound (MicroUS) is a novel imaging modality relying on a high-frequency transducer which confers a three-fold improvement in spatial resolution as compared with conventional transrectal ultrasound. We evaluated the diagnostic value of MRI-MicroUS fusion biopsy and determined the additional benefit of employing MicroUS.
Retrospective analysis of consecutive treatment-naïve men undergoing MRI-MicroUS fusion biopsy between May 2018 and March 2019. Pre-biopsy MRI was systematically reviewed in a dedicated meeting where suspicious lesions PIRADS≥3 were registered and uploaded in the ExactVu MicroUS device. MRI and MicroUS lesions were individually marked in a PIRADS v2 scheme. The biopsy protocol included MRI-MicroUS fusion and MicroUS targeted biopsies; systematic biopsies were performed at clinician's discretion. The diagnostic value was evaluated in terms of detection rate of clinically significant prostate cancer, defined as Gleason pattern≥4 at histology.
In all, 148 patients with a median age of 69 years (IQR 63-74) and median PSA density of 0.16ng/ml/cc (0.10-0.23) were included. Clinically significant cancer was detected in 42.5% (63/148) patients. MRI detected 89 lesions in the peripheral zone; 73% (65/89) were visible on MicroUS. Clinically significant cancer was detected in 46.1% (30/65) MRI and MicroUS visible lesions, and in 4.2% (1/24) lesions only visible on mpMRI. MicroUS additionally identified 35 suspicious lesions non-visible on MRI of which clinically significant cancer was present in 25.7% (9/35).
Adding MicroUS to the conventional pathway seems to increase the detection rate of clinically significant disease in unselected men undergoing biopsy.
Keywords
Biopsie de la prostate, Cancer de la prostate, Imagerie par résonance magnétique, Magnetic resonance imaging, Micro-échographie, Microultrasound, Prostate biopsy, Prostate cancer
Pubmed
Create date
18/03/2022 13:11
Last modification date
05/05/2022 6:34
Usage data